ROCKVILLE, Md.--(BUSINESS WIRE)--Bacilligen, Inc. announced today that it has filed patent applications covering two of its platform technologies. The first filing covers rMB, Bacilligen’s improved bladder cancer therapy, and the second, BVS, Bacilligen’s bacteriophage-based capsid vector system for delivery of genetic vaccines and therapeutics, and rapid biological manufacturing.
